doi: 10.1016/0039-128x(91)90003-e.
Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5 alpha-reductase inhibitor
Affiliations
- PMID: 1666698
- DOI: 10.1016/0039-128x(91)90003-e
Item in Clipboard
Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5 alpha-reductase inhibitor
Steroids.
1991 Sep.
Abstract
The hormonal effects following the acute (single dose) administration of a 4-azasteroid inhibitor of 5 alpha-reductase (MK-906) were evaluated in 10 healthy male volunteers. Marked suppression of serum dihydrotestosterone (DHT) was observed after the administration of single doses as low as 12.5 mg. The mean percent decrease in DHT at 24 hours in the group treated with a single 25-mg dose was 56% +/- 10% compared with the baseline. The suppression of plasma DHT levels continued for up to 72 hours. This study demonstrates that administration of single oral doses (12.5 to 400 mg) of MK-906 results in a significant decrease in the conversion of testosterone to DHT.
Similar articles
-
Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans.Prostate. 1989;14(1):45-53. doi: 10.1002/pros.2990140106. Prostate. 1989. PMID: 2538808
-
MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.J Clin Endocrinol Metab. 1997 May;82(5):1373-7. doi: 10.1210/jcem.82.5.3912. J Clin Endocrinol Metab. 1997. PMID: 9141518 Clinical Trial.
-
Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers.Eur J Drug Metab Pharmacokinet. 1991 Jan-Mar;16(1):15-21. doi: 10.1007/BF03189869. Eur J Drug Metab Pharmacokinet. 1991. PMID: 1657611 Clinical Trial.
-
Finasteride: the first 5 alpha-reductase inhibitor.Pharmacotherapy. 1993 Jul-Aug;13(4):309-25; discussion 325-9. Pharmacotherapy. 1993. PMID: 7689728 Review.
-
The clinical development of a 5 alpha-reductase inhibitor, finasteride.J Steroid Biochem Mol Biol. 1990 Nov 20;37(3):375-8. doi: 10.1016/0960-0760(90)90487-6. J Steroid Biochem Mol Biol. 1990. PMID: 1701660 Review.
Cited by
-
Clinical pharmacokinetics and pharmacodynamics of finasteride.Clin Pharmacokinet. 1996 Jan;30(1):16-27. doi: 10.2165/00003088-199630010-00002. Clin Pharmacokinet. 1996. PMID: 8846625 Review.
-
Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.Drugs. 1993 Jul;46(1):177-208. doi: 10.2165/00003495-199346010-00010. Drugs. 1993. PMID: 7691505 Review.
-
Medical treatment of benign prostatic hyperplasia.Postgrad Med J. 2007 Feb;83(976):73-8. doi: 10.1136/pgmj.2006.050724. Postgrad Med J. 2007. PMID: 17308208 Free PMC article. Review.
-
Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Rev Endocr Metab Disord. 2015 Sep;16(3):177-98. doi: 10.1007/s11154-015-9319-y. Rev Endocr Metab Disord. 2015. PMID: 26296373 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
